Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
Rank in Stocks #33635
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Share Price
$0.03702159
Last synced: 2024-01-29
Market Cap
$7.21M
Change (1 day)
-3.08%
Change (1 year)
0.00%
Country
AU
Trade Antisense Therapeutics Limited (ANP)

Category

Stock split history for Antisense Therapeutics Limited (ANP)
Antisense Therapeutics Limited stock (symbol: ANP) underwent a total of 0 stock splits.
The most recent stock split occurred on Aug 17, 2026.
One ANP share bought prior to Aug 17, 2026 would equal to 0 ANP shares today.
Stock split list
Year Split Multiple Cumulative Multiple
Not enough data for the provided dates.
Stock splits for similar companies or competitors